Bolt Biotherapeutics CEO Quinn sells $58,402 in stock

William P. Quinn, the President, CEO, and CFO of Bolt Biotherapeutics, Inc., divested a total of $58,402 worth of common stock over three days in September 2026. The stock prices during this period ranged from $3.15 to $4.14. These transactions were made to cover tax withholding obligations related to the vesting of restricted stock units granted on October 22, 2025.

Quinn's stock sales came at a time when the stock experienced a decline of 11% over the previous week and a 34% decrease year-to-date. Despite this recent slump, InvestingPro analysis suggests the stock is currently undervalued, trading near its 52-week low of $3.10. It is noteworthy that Quinn had previously acquired shares of Bolt Biotherapeutics in June 2026, purchasing 637 shares at a price of $3.876 per share, totaling $2,469, through the company's Employee Stock Purchase Plan.